Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · IEX Real-Time Price · USD
12.09
-0.08 (-0.66%)
Jul 2, 2024, 4:30 PM EDT - Market closed
Company Description
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases.
It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.
The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020.
The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Mineralys Therapeutics, Inc.
Country | United States |
Founded | 2019 |
IPO Date | Feb 10, 2023 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 28 |
CEO | Jon Congleton |
Contact Details
Address: 150 N. Radnor Chester Road, Suite F200 Radnor, Pennsylvania 19087 United States | |
Phone | (888) 378-6240 |
Website | mineralystx.com |
Stock Details
Ticker Symbol | MLYS |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $16.00 |
CIK Code | 0001933414 |
CUSIP Number | 603170101 |
ISIN Number | US6031701013 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Jon Congleton | Chief Executive Officer and Director |
Adam Scott Levy | Chief Financial Officer and Secretary |
Dr. David M. Rodman M.D. | Chief Medical Officer |
Dr. Brian Taylor Slingsby M.D., M.P.H., Ph.D. | Founder and Executive Chairman |
Cindy Berejikian | Executive Vice President of Operations |
Sarah Foster | Vice President of Human Resources |
Dr. Robert McKean Ph.D. | Senior Vice President of CMC |
Danielle Bradbury | Senior Vice President of Quality Assurance |
Jeffrey N. Fellows | Senior Vice President of Regulatory Affairs |
Jessica Ibbitson | Senior Vice President of Clinical Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 20, 2024 | 144 | Filing |
Jun 18, 2024 | 144 | Filing |
Jun 17, 2024 | 144 | Filing |
Jun 14, 2024 | 144 | Filing |
Jun 14, 2024 | 8-K | Current Report |
Jun 13, 2024 | 144 | Filing |
Jun 12, 2024 | 144 | Filing |
Jun 11, 2024 | 144 | Filing |
Jun 10, 2024 | 8-K | Current Report |
May 31, 2024 | 8-K | Current Report |